Director/PDMR Shareholding

RNS Number : 1735B

Tissue Regenix Group PLC

29 September 2022

 

Tissue Regenix Group plc

("Tissue Regenix", the "Company" or "the Group")

Director/PDMR Shareholding

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that on 28 September 2022, Daniel Lee, Chief Executive Officer, bought 2,000,000 Ordinary Shares in the Group at a price of 0.485 pence per share for a total consideration of $10,409.41.

As a result, Daniel Lee holds 7,262,200 Ordinary Shares in the Company representing 0.10% of the total issued share capital.

For more information:

Tissue Regenix Group plc	www.tissueregenix.com
David Cocke, Chief Financial Officer	Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)		Tel:  [phone]
Ben Maddison / Nick Harland
Walbrook PR Ltd		Tel: [phone]
Alice Woodings / Lianne Applegarth		[e-mail]

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Daniel Lee
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJI36
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.1p each
	Identification code	GB00B5SGVL29
b)	Nature of the transaction	Purchase
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			0.485	2,000,000
d)	Aggregated information
	- Aggregated volume	2,000,000
	- Price	$10,409.41
e)	Date of the transaction	28 September 2022
f)	Place of the transaction	London Stock Exchange, AIM Market

About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle, and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.

 

END

 

 

DSHGCGDCBBDDGDC